Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $2.8 billion.

  • Ptc Therapeutics' Total Liabilities fell 335.33% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year decrease of 335.33%. This contributed to the annual value of $2.8 billion for FY2024, which is 327.32% up from last year.
  • As of Q3 2025, Ptc Therapeutics' Total Liabilities stood at $2.8 billion, which was down 335.33% from $2.8 billion recorded in Q2 2025.
  • Ptc Therapeutics' 5-year Total Liabilities high stood at $2.9 billion for Q3 2024, and its period low was $1.8 billion during Q3 2022.
  • For the 5-year period, Ptc Therapeutics' Total Liabilities averaged around $2.3 billion, with its median value being $2.1 billion (2022).
  • As far as peak fluctuations go, Ptc Therapeutics' Total Liabilities soared by 10595.1% in 2021, and later plummeted by 520.91% in 2022.
  • Over the past 5 years, Ptc Therapeutics' Total Liabilities (Quarter) stood at $1.9 billion in 2021, then increased by 5.99% to $2.1 billion in 2022, then soared by 32.23% to $2.7 billion in 2023, then rose by 3.27% to $2.8 billion in 2024, then dropped by 0.13% to $2.8 billion in 2025.
  • Its Total Liabilities stands at $2.8 billion for Q3 2025, versus $2.8 billion for Q2 2025 and $2.8 billion for Q1 2025.